While European guidelines recommend topical therapy, phototherapy, or acitretin for patients with recent malignancy, the use of IL-17 and IL-23 inhibitors may be considered in individuals with active disease significantly impacting their quality of life. The gene discussed is IL37; the disease is cancer.